Aileron Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ALRN and buy or sell other stocks, ETFs, and their options commission-free!About ALRN
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.
CEOBrian J. Windsor, PhD
CEOBrian J. Windsor, PhD
Employees11
Employees11
HeadquartersAustin, Texas
HeadquartersAustin, Texas
Founded2001
Founded2001
Employees11
Employees11
ALRN Key Statistics
Market cap95.28M
Market cap95.28M
Price-Earnings ratio-0.77
Price-Earnings ratio-0.77
Dividend yield—
Dividend yield—
Average volume70.18K
Average volume70.18K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.40
52 Week high$4.40
52 Week low$1.35
52 Week low$1.35
People also own
Based on the portfolios of people who own ALRN. This list is generated using Robinhood data, and it’s not a recommendation.